This study characterizes KPC-2 producing Klebsiella pneumoniae belonging to ST101. Whole genome sequencing using the Ion Torrent PGM platform with 400 bp chemistry was performed. bla KPC-2 was found on an IncFII K plasmid associated with ISKpn6 and ISKpn7 without Tn4401. This is the first report of KPC-2 K. pneumoniae from bacteremia in India. The isolate also coded for other resistance genes such as aadA1, aadA2, armA, aac(3)-Ild, aac(6¢)-Ild for aminoglycoside; bla SHV-11 , bla TEM-1B , bla OXA-9 , for b-lactams and aac(6¢)-Ild, oqxA, oqxB, qnrB1 for fluoroquinolones. It belonged to the K17 capsular type. India is endemic to New Delhi metallo-b-lactamase and OXA48-like carbapenemases and K. pneumoniae carbapenemase (KPC) is seldom reported. With high rates of carbapenem resistance, emergence of KPC in India will challenge patient management. The isolate was susceptible to colistin. The patient had a fatal outcome.
. Tn4401 is known to carry ISKpn6 and ISKpn7 flanking bla KPC . ST101 carrying bla KPC is an international epidemic clone among K. pneumoniae reported from various regions [12, 13] . This is the first report of K. pneumoniae of international clone ST101 harbouring bla KPC without Tn4401 from India.
K. pneumoniae was isolated from central line culture. It was identified by standard culture and biochemical methods [14] . Identification was also confirmed by Vitek-MS (bioMerieux, France). String test was performed to screen for hypermucoviscous phenotype. The antimicrobial susceptibility testing for antimicrobials such as cefotaxime (30 µg), ceftazidime (30 µg); piperacillin/tazobactam (100/ 10 µg); imipenem (10 µg), meropenem (10 µg); ciprofloxacin (5 µg), levofloxacin (5 µg), amikacin (30 µg), gentamicin (10 µg), minocycline (30 µg) and tigecycline (15 µg) was performed for the isolate by the Kirby Bauer disk diffusion method as recommended by the Clinical Laboratory Standards Institute (CLSI) and interpreted according to CLSI 2016 guidelines [15] . Tigecycline susceptibility was interpreted according to FDA breakpoints (www.accessdata.fda.gov/drugsatfda_docs/label/ 2009/021821s016lbl.pdf).
Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as the control strains for susceptibility testing. In-house CarbaNP test as recommended by CLSI for the detection of carbapenemase activity was performed. MIC was determined for first and second line antimicrobials with the Vitek2 AST system (Biomerieux). Colistin susceptibility was determined by broth-micro dilution using mcr-1 E. coli (Courtesy: Dr Olga Perovic, National Institute for Communicable Diseases, Johannesburg) as the positive control and E. coli ATCC 25922 as the negative control. The result was interpreted according to EUCAST 2016 guidelines [16] .
DNA was extracted using Qiasymphony (Qiagen) as per the manufacturer's instructions. The isolate was subjected to whole genome sequencing using the Ion Torrent PGM platform with 400 bp chemistry. Raw reads were assembled using Assembler SPAdes v.5.0 software in Torrent suite server version 4.4.3. The genome was annotated using RAST (Rapid Annotation using Subsystems Technology http://rast.nmpdr.org/), Patric (Pathosystems Resource Integration Centre www.patricbrc.org/) and the National Centre for Biotechnology Information Prokaryotic Genome Automatic Annotation Pipeline (PGAAP) softwares. The resistance genes were identified using ResFinder version 2.1 (https://cge.cbs.dtu.dk/services/ResFinder/) and multi-locus sequence typing (MLST) was determined using the database at https://cge.cbs.dtu.dk/services/MLST/. Plasmids present in the genome were identified by PlasmidFinder version 1.3 available at https://cge.cbs.dtu.dk/services/PlasmidFinder/. CRISPR loci in the genomes were identified by CRISPRFinder at http://crispr.i2bc.paris-saclay.fr/Server/. The insertion sequence associated with bla KPC was identified using ISfinder (www-is.biotoul.fr/).
The clinical details of the patient were obtained from electronic medical record.
By disc diffusion, the isolate was found to be resistant to all antimicrobials except tigecycline, colistin and chloramphenicol. String test was negative and the isolate lacked rmpA/ rmpA2 genes which are markers of hypervirulent strains. The isolate was positive for the modified Hodge test and inhouse CarbaNP. MIC for meropenem and minocycline as obtained by Vitek2 were !16 and 8 µg ml À1 respectively. Colistin MIC as determined by broth-micro dilution was 2 µg ml À1 .
The genome coverage was 45.5X. A total of 640 contigs were obtained with 309 being >500 bp. The total number of scaffolds were 637 and N50 of all scaffolds was 43 654. The results of ResFinder showed the presence of the following genes: aadA1, aadA2, armA, aac(3)-Ild, aac(6¢)-Ild for aminoglycoside; bla SHV-11 , bla TEM-1B , bla OXA-9 , bla KPC-2 for b-lactams; aac(6¢)-Ild, oqxA, oqxB, qnrB1 for fluoroquinolones; mph(E), msr(E) for macrolide-lincosamide; fosA for fosfomycin; sul1 for sulphonamides and dfrA1 for trimethoprim. It belonged to ST101 containing three plasmids namely IncFII K , IncFIB K and IncR. The isolate did not contain CRISPRs. The isolate belonged to the K17 capsular type which was identified based on the wzc sequence from the whole genome. Wzc codes for tyrosine kinase were involved in capsular polysaccharide biosynthesis and assembly [17] . bla KPC-2 was flanked by ISKpn6 belonging to the IS1182 family and also ISKpn7 belonging to the IS21 family transposase, as illustrated in Fig. 1 .
The isolate was from a middle-aged patient who presented with fever for 1 month with recurrent vomiting and severe headache since 1 week. It was a known case of medium vessel vasculitis for which the patient received immunosuppressant elsewhere. Central line and peripheral blood cultures were drawn. The central line culture grew carbapenem-resistant K. pneumoniae and peripheral blood cultures remained sterile. The central line was removed and the patient was started on colistin and meropenem in renal adjusted doses. But the patient continued to worsen and developed respiratory fatigue and acute type II respiratory failure requiring emergency intubation. Due to refractory hypotension, the patient succumbed to disease in 2 days. This is the first report of KPC-2 K. pneumoniae from bacteraemia belonging to ST101 from India. Earlier, in the study centre, NDM and OXA48-like carbapenemases were prevalent and KPC was absent [2] . Diverse plasmid types such as IncX3, IncFII K , IncFIA have been reported to contain bla KPC-2 [7] . Further, in the present study, bla KPC-2 was located on an IncFII K plasmid. Transposon Tn4401 is commonly associated with bla KPC-2 but in the present study, the transposon was absent. Along with ISKpn6 and ISKpn7, the Tn4401 transposon contains genes such as tnpA coding for a transposase and tnpR coding for resolvase which are essential for transposon functioning [5] . As illustrated in Fig. 1 , the isolate in the present study lacked the tnpA and tnpR genes. Interestingly, ISKpn6 and ISKpn7 would have initiated the transmission in the absence of this transposon. Although bla KPC-2 was adjacent to ISKpn6, a hypothetical protein and AAA ATPase were present between bla KPC-2 and ISKpn7. Notably, the diversity of genetic elements associated with bla KPC-2 is large and has the potential to spread rapidly in the hospital environment. In K. pneumoniae, bla KPC was reported to be associated with mutated bla TEM , where the combo was flanked by ISKpn6 and ISKpn8. Interestingly, ISKpn7 was absent, which was reported in most of the cases [18] . bla KPC being flanked by ISKpn6 and ISKpn8 has also been reported [19] . Tn4401d in ST258 K. pneumoniae was reported from which a partial bla KPC fragment had been excised along with ISKpn7 and a partial tnpA fragment [20] .
KPC producing P. aeruginosa and A. baumannii are seldom reported when compared to K. pneumoniae. In P. aeruginosa, two different genetic arrangements were observed for bla KPC , one with the absence of ISKpn7 in Tn4401b on an IncP plasmid [18] while in the other bla KPC-2 flanked by ISKpn6 and ISKpn7. Similarly, in A. baumannii, bla KPC-2 is flanked by ISKpn6 and ISKpn7 was identified in Tn4401h, a truncated form of Tn4401e, in an IncA/C plasmid fragment incorporated into the chromosome [21] . Several isoforms of Tn4401 have been associated with bla KPC among different organisms.
KPC-2 K. pneumoniae belonging to ST101 has been reported in other countries such as Italy and Spain but not in India [12, 13] . KPC K. pneumoniae is associated with international epidemic clone ST258 and also the CG258. To date, these clonal types have not been reported from India. K. pneumoniae belonging to ST101 coding for ArmA and KPC was seen in Italy similar to the present study isolate [22] .
Earlier, KPC-2 K. pneumoniae isolated from urine specimen in India was published by Kumarasamy et al. [23] which also produced NDM-1, CTX-M-15, SHV-12, TEM-1 and OXA-1. Another study in India reports the co-existence of bla KPC-2 and bla NDM-1 among clinical isolates of P. aeruginosa [24] . However, the present study isolate did not produce other carbapenemases. The emergence of KPC in India could lead to a change in the existing trend in prevailing carbapenemases. The isolate remains susceptible to reserve drugs such as tigecycline and colistin. However, increased usage of these antimicrobials in-turn leads to resistance, leaving no options for therapy.
KPC is plasmid-mediated, its presence in the hospital setting can be a threat to infection control as it can rapidly disseminate among other members of Enterobacteriaceae. The diversity of mobile genetic elements associated with KPC increases its potential to cause epidemics. Isolation of KPC-2 producing K. pneumoniae of ST101 harbouring ISKpn6 and ISKpn7 leaves India under equal threat of a KPC epidemic as the rest of the world. In India, with high rates of carbapenem resistance, emergence of KPC can lead to organisms with different carbapenemases which will challenge patient management. Surveillance of existing resistance mechanisms will help in administering appropriate empirical therapy.
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